GlassScriptPhysician profile
James R Ware
NPI 1336540715
$2,773.83
in general payments reported to CMS, 2019-2025
23 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $788 · 2022: $745 · 2023: $437 · 2024: $526 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,241.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $576.10 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $228.28 | 2023-2025 | Xifaxan |
| Avanir Pharmaceuticals, INC. | $206.47 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $157.75 | 2024 | Ultomiris |
| Abbvie INC. | $143.33 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.27 | 2023-2025 | Jardiance, Spiriva Respimat |
| Lundbeck LLC | $125.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $124.99 | 2023 | Spravato |
| Teva Pharmaceuticals USA, INC. | $119.28 | 2022 | |
| Access Pro Medical, LLC | $111.37 | 2023 | Matriderm |
| Jazz Pharmaceuticals INC. | $110.72 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $107.07 | 2021-2022 | |
| Inari Medical, INC. | $102.55 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Axsome Therapeutics, INC. | $98.69 | 2025 | Auvelity |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $66.86 | 2023-2024 | Dificid, Zerbaxa |
| Astrazeneca Pharmaceuticals LP | $62.60 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $44.94 | 2023 | Terlivaz |
| Pfizer INC. | $39.61 | 2021 | |
| Amgen INC. | $34.53 | 2024 | Evenity, Prolia |
| Philips North America LLC | $24.19 | 2024 | (Cm9) Amb Mon & Diag Und |
| Mylan Specialty L.P. | $17.85 | 2024 | Yupelri |
| Medtronic, INC. | $16.38 | 2023 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.